Lumida
/ZVRA
⌘K
Zevra Therapeutics Inc

Zevra Therapeutics Inc

ZVRA
$12.77USD+0.08%+0.01 today

MARKET CAP

754.9M

P/E (TTM)

8.0x

FWD P/E

14.6x

DAY RANGE

$12 – $13

52W RANGE

$7
$15

AI Summary

Stalk
Sell NowMedium

ZVRA is in Stage 3 distribution following a decisive Support Failure, with medium-term bias firmly bearish. Short-term price trades below declining 9EMA and 20EMA, rejecting rallies at EMA resistance. Execution is Sell Now into the EMA resistance zone, while key risks include potential support at the rising 50SMA and short-term relief bounces.

  • Q1 net revenue reached $36.2M (+78% YoY), signaling robust MyPlypha demand.
  • Patent protection extended through November 2041, reducing exclusivity risk and raising price targets to $29.
  • European approval process remains uncertain, with label and pricing outcomes undetermined.
Full analysis →
Insider Trades19 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 22, 2026SellZVRARahsaan ThompsonChief Legal & Compliance34,557$12.68$754.9M-15.06%+78.35%$438.3K-19.04%10b5-1Sell Now
May 11, 2026SellZVRARahsaan ThompsonChief Legal & Compliance1,794$11.30$754.9M-15.06%+78.35%$20.3K-3.59%10b5-1Sell Now
Feb 9, 2026SellZVRANeil F. McfarlanePresident and CEO14,625$8.56$754.9M-15.06%+78.35%$125.2K-3.07%10b5-1Sell Now
Feb 3, 2026SellZVRATimothy J. SangiovanniSVP, Finance & Corp Controller3,000$9.18$754.9M-15.06%+78.35%$27.5K-9.21%10b5-1Sell Now
Feb 3, 2026SellZVRAJoshua SchaferCCO10,500$9.19$754.9M-15.06%+78.35%$96.5K-14.43%10b5-1Sell Now
Feb 2, 2026SellZVRANeil F. McfarlanePresident and CEO91,000$9.38$754.9M-15.06%+78.35%$853.4K-8.56%10b5-1Sell Now
Jan 30, 2026SellZVRATimothy J. SangiovanniSVP, Finance & Corp Controller1,750$8.82$754.9M-15.06%+78.35%$15.4K-3.72%10b5-1Sell Now
Jan 30, 2026SellZVRAJoshua SchaferCCO3,375$8.83$754.9M-15.06%+78.35%$29.8K-1.60%10b5-1Sell Now
Jan 30, 2026SellZVRARahsaan ThompsonChief Legal & Compliance4,080$8.83$754.9M-15.06%+78.35%$36.0K-2.16%10b5-1Sell Now
Jan 30, 2026SellZVRAAdrian W QuartelChief Medical Officer4,533$8.83$754.9M-15.06%+78.35%$40.0K-3.03%10b5-1Sell Now
Oct 10, 2025SellZVRANeil F. McfarlanePresident and CEO19,500$10.82$754.9M-15.06%+78.35%$210.9K-5.71%10b5-1Sell Now
Jun 26, 2025SellZVRARahsaan ThompsonChief Legal & Compliance24,000$9.21$754.9M-15.06%+78.35%$221.0K-36.00%10b5-1Sell Now
Feb 13, 2025SellZVRATimothy J. SangiovanniSVP, Finance & Corp Controller3,000$7.86$754.9M-15.06%+78.35%$23.6K-15.51%10b5-1Sell Now
Feb 13, 2025SellZVRAJoshua SchaferCCO & EVP, Bus. Development10,500$7.86$754.9M-15.06%+78.35%$82.5K-26.26%10b5-1Sell Now
Feb 13, 2025SellZVRAR. Laduane CliftonCFO & Treasurer11,000$7.86$754.9M-15.06%+78.35%$86.5K-17.64%10b5-1Sell Now
Feb 13, 2025SellZVRANeil F. McfarlanePresident and CEO91,817$7.92$754.9M-15.06%+78.35%$727.4K-18.17%10b5-1Sell Now
Jul 17, 2024BuyZVRAR. Laduane CliftonCFO & Treasurer2,000$6.77$754.9M-15.06%+78.35%$13.5K+12.14%Sell Now
Sep 6, 2023BuyZVRAR. Laduane CliftonCFO, Secretary & Treasurer1,000$4.96$754.9M-15.06%+78.35%$5.0K+6.99%Sell Now
Sep 5, 2023BuyZVRAJoshua SchaferCCO & EVP, Bus. Development500$5.13$754.9M-15.06%+78.35%$2.6K+16.67%Sell Now